Drug Fix: BrainStorm’s ALS Adcomm, Batch Testing Imported Drugs, US FDA’s First In-Person Meeting

Pink Sheet reporters and editors discuss the FDA’s upcoming advisory committee meeting for the controversial ALS cell therapy NurOwn, a proposal to batch test all drugs coming into the US amid problems conducting foreign inspections, and the FDA’s return to in-person meetings with industry.

More On These Topics From The Pink Sheet:
https://pink.pharmaintelligence.informa.com/PS147942/BrainStorms-ALS-Treatment-NurOwn-Filed-Over-Protest-Will-Get-US-FDA-Panel-Review
https://pink.pharmaintelligence.informa.com/PS147972/Batch-Testing-Of-All-Imported-Drugs-Floated-At-House-Appropriations-Hearing
https://pink.pharmaintelligence.informa.com/PS147971/US-FDA-Holds-First-Hybrid-Meeting-With-Industry